Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer

PURPOSE: Approximately 20% of patients with RAS wild-type metastatic colorectal cancer (mCRC) experience objective responses to the anti-EGFR antibody cetuximab, but disease eradication is seldom achieved. The extent of tumor shrinkage correlates with long-term outcome. We aimed to find rational com...

Descripción completa

Detalles Bibliográficos
Autores principales: Leto, Simonetta M., Ferri, Martina, Sassi, Francesco, Zanella, Eugenia R., Cottino, Francesca, Vurchio, Valentina, Catalano, Irene, Ferrero, Alessandro, Zingaretti, Caterina C., Marchiò, Caterina, Grassi, Elena, Trusolino, Livio, Bertotti, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011886/
https://www.ncbi.nlm.nih.gov/pubmed/36622698
http://dx.doi.org/10.1158/1078-0432.CCR-22-2550

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011886/
https://www.ncbi.nlm.nih.gov/pubmed/36622698
http://dx.doi.org/10.1158/1078-0432.CCR-22-2550

Ejemplares similares